| __timestamp | Exelixis, Inc. | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 1595000 |
| Thursday, January 1, 2015 | 96351000 | 11434000 |
| Friday, January 1, 2016 | 95967000 | 26546000 |
| Sunday, January 1, 2017 | 112171000 | 39778000 |
| Monday, January 1, 2018 | 182257000 | 53418000 |
| Tuesday, January 1, 2019 | 336964000 | 111997000 |
| Wednesday, January 1, 2020 | 547851000 | 139507000 |
| Friday, January 1, 2021 | 693716000 | 195958000 |
| Saturday, January 1, 2022 | 891813000 | 248149000 |
| Sunday, January 1, 2023 | 1044071000 | 232366000 |
| Monday, January 1, 2024 | 910408000 |
Unlocking the unknown
In the competitive landscape of biotechnology, innovation is the lifeblood of success. Over the past decade, Exelixis, Inc. and ImmunityBio, Inc. have been at the forefront of this race, investing heavily in research and development (R&D) to drive breakthroughs. From 2014 to 2023, Exelixis has consistently outpaced ImmunityBio in R&D spending, with a staggering 450% increase, peaking at over $1 billion in 2023. In contrast, ImmunityBio's investment grew by approximately 145% during the same period, reaching around $232 million.
This significant disparity highlights Exelixis's aggressive strategy to maintain its competitive edge. The data underscores the importance of sustained investment in R&D for biotech companies aiming to lead in innovation. As the industry evolves, these investments will likely play a crucial role in shaping the future of healthcare and treatment options.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Exelixis, Inc.
R&D Insights: How Novartis AG and Exelixis, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Exelixis, Inc.
Research and Development Investment: Insmed Incorporated vs Exelixis, Inc.
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Exelixis, Inc. vs Wave Life Sciences Ltd.
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
R&D Spending Showdown: CymaBay Therapeutics, Inc. vs ImmunityBio, Inc.